Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

162 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial.
Omata M, Nishiguchi S, Ueno Y, Mochizuki H, Izumi N, Ikeda F, Toyoda H, Yokosuka O, Nirei K, Genda T, Umemura T, Takehara T, Sakamoto N, Nishigaki Y, Nakane K, Toda N, Ide T, Yanase M, Hino K, Gao B, Garrison KL, Dvory-Sobol H, Ishizaki A, Omote M, Brainard D, Knox S, Symonds WT, McHutchison JG, Yatsuhashi H, Mizokami M. Omata M, et al. Among authors: nishigaki y. J Viral Hepat. 2014 Nov;21(11):762-8. doi: 10.1111/jvh.12312. Epub 2014 Sep 8. J Viral Hepat. 2014. PMID: 25196837 Clinical Trial.
Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study.
Okita K, Izumi N, Matsui O, Tanaka K, Kaneko S, Moriwaki H, Ikeda K, Osaki Y, Numata K, Nakachi K, Kokudo N, Imanaka K, Nishiguchi S, Okusaka T, Nishigaki Y, Shiomi S, Kudo M, Ido K, Karino Y, Hayashi N, Ohashi Y, Makuuchi M, Kumada H; Peretinoin Study Group. Okita K, et al. Among authors: nishigaki y. J Gastroenterol. 2015 Feb;50(2):191-202. doi: 10.1007/s00535-014-0956-9. Epub 2014 Apr 13. J Gastroenterol. 2015. PMID: 24728665 Free PMC article. Clinical Trial.
Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial.
Mizokami M, Yokosuka O, Takehara T, Sakamoto N, Korenaga M, Mochizuki H, Nakane K, Enomoto H, Ikeda F, Yanase M, Toyoda H, Genda T, Umemura T, Yatsuhashi H, Ide T, Toda N, Nirei K, Ueno Y, Nishigaki Y, Betular J, Gao B, Ishizaki A, Omote M, Mo H, Garrison K, Pang PS, Knox SJ, Symonds WT, McHutchison JG, Izumi N, Omata M. Mizokami M, et al. Among authors: nishigaki y. Lancet Infect Dis. 2015 Jun;15(6):645-53. doi: 10.1016/S1473-3099(15)70099-X. Epub 2015 Apr 8. Lancet Infect Dis. 2015. PMID: 25863559 Clinical Trial.
No increased risk of hepatocellular carcinoma after eradication of hepatitis C virus by direct-acting antivirals, compared with interferon-based therapy.
Korenaga M, Murata K, Izumi N, Tamaki N, Yokosuka O, Takehara T, Sakamoto N, Suda G, Nishiguchi S, Enomoto H, Ikeda F, Yanase M, Toyoda H, Genda T, Umemura T, Yatsuhashi H, Yamasaki K, Ide T, Toda N, Kanda T, Nirei K, Ueno Y, Haga H, Nishigaki Y, Nakane K, Omata M, Mochizuki H, Aoki Y, Imamura M, Kanto T, Mizokami M. Korenaga M, et al. Among authors: nishigaki y. Glob Health Med. 2022 Aug 31;4(4):216-224. doi: 10.35772/ghm.2022.01026. Glob Health Med. 2022. PMID: 36119787 Free PMC article.
Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial.
Okita K, Izumi N, Ikeda K, Osaki Y, Numata K, Ikeda M, Kokudo N, Imanaka K, Nishiguchi S, Kondo S, Nishigaki Y, Shiomi S, Ueshima K, Isoda N, Karino Y, Kudo M, Tanaka K, Kaneko S, Moriwaki H, Makuuchi M, Okusaka T, Hayashi N, Ohashi Y, Kumada H; Peretinoin Study Group. Okita K, et al. Among authors: nishigaki y. J Gastroenterol. 2015 Jun;50(6):667-74. doi: 10.1007/s00535-014-0996-1. Epub 2014 Sep 11. J Gastroenterol. 2015. PMID: 25209978 Free PMC article.
Hepatitis E virus subtype 3f strains isolated from Japanese hepatitis patients with no history of travel to endemic areas - The origin analyzed by molecular evolution.
Nakano T, Takahashi M, Takahashi K, Nagashima S, Suzuki Y, Nishigaki Y, Tomita E, Okano H, Oya Y, Shiraki K, Takase K, Sugimoto K, Koyama J, Mizuo H, Ikezawa K, Aikawa T, Arai M, Okamoto H. Nakano T, et al. Among authors: nishigaki y. Virology. 2018 Jan 1;513:146-152. doi: 10.1016/j.virol.2017.08.008. Epub 2017 Oct 24. Virology. 2018. PMID: 29078116 Free article.
Changes in ALBI Score and PIVKA-II within Three Months after Commencing Atezolizumab Plus Bevacizumab Treatment Affect Overall Survival in Patients with Unresectable Hepatocellular Carcinoma.
Unome S, Imai K, Takai K, Miwa T, Hanai T, Nishigaki Y, Hayashi H, Kochi T, Shimizu S, Nagano J, Iritani S, Suetsugu A, Shimizu M. Unome S, et al. Among authors: nishigaki y. Cancers (Basel). 2022 Dec 10;14(24):6089. doi: 10.3390/cancers14246089. Cancers (Basel). 2022. PMID: 36551574 Free PMC article.
Hepatocellular carcinoma patients with increased oxidative stress levels are prone to recurrence after curative treatment: a prospective case series study using the d-ROM test.
Suzuki Y, Imai K, Takai K, Hanai T, Hayashi H, Naiki T, Nishigaki Y, Tomita E, Shimizu M, Moriwaki H. Suzuki Y, et al. Among authors: nishigaki y. J Cancer Res Clin Oncol. 2013 May;139(5):845-52. doi: 10.1007/s00432-013-1389-1. Epub 2013 Feb 15. J Cancer Res Clin Oncol. 2013. PMID: 23411687 Free article.
Insulin resistance raises the risk for recurrence of stage I hepatocellular carcinoma after curative radiofrequency ablation in hepatitis C virus-positive patients: A prospective, case series study.
Imai K, Takai K, Nishigaki Y, Shimizu S, Naiki T, Hayashi H, Uematsu T, Sugihara J, Tomita E, Shimizu M, Nagaki M, Moriwaki H. Imai K, et al. Among authors: nishigaki y. Hepatol Res. 2010 Apr;40(4):376-82. doi: 10.1111/j.1872-034X.2009.00616.x. Epub 2010 Mar 4. Hepatol Res. 2010. PMID: 20236359
162 results